SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4630)9/10/2001 12:47:16 PM
From: tom pope  Read Replies (1) | Respond to of 52153
 
posting this here because the IDPH thread is not very lively. The market seems to be unimpressed. From Briefing

11:18 ET IDEC Pharm (IDPH) 58.86 +1.25 (+2.1%): FDA staff finds company's experimental cancer drug Zevalin was effective in treating certain types of non-Hodgkins lymphomas (NHLs) for which other therapies have failed. The drug will go before an FDA advisory panel tomorrow. (Reuters)



To: Biomaven who wrote (4630)9/10/2001 1:12:39 PM
From: tom pope  Respond to of 52153
 
If I remember correctly, that article was written after the market had already turned, though that was not recognized until later.
What's most interesting are the valuations the market reached at that time, p/b for one. At that time it was regarded as a given that banks always traded at a discount to book value, now C is 3 times book


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News